首页|丝素蛋白纳米载体在抗肿瘤药物递送系统中的应用进展

丝素蛋白纳米载体在抗肿瘤药物递送系统中的应用进展

Progress on Application of Silk Fibroin Nanocarriers in Oncology Drug Delivery System

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
丝素蛋白(silk fibroin)是一种天然高分子材料,因其具有良好的生物相容性、生物可降解性、结构可修饰性、低细胞毒性以及无免疫原性而被广泛应用于抗肿瘤药物递送.抗肿瘤药物大都具有溶解度低、药物代谢动力学特征差和靶外毒性高的缺点,因此,寻找和使用合适的药物递送系统解决抗肿瘤药物的这些问题已成为当务之急.本文简要综述了丝素蛋白的结构、特点,丝素蛋白纳米载体的制备及其用于抗肿瘤药物递送的类型及研究进展,并综述了丝素蛋白纳米载体应用于光动力治疗、光热治疗以及基因治疗中治疗恶性肿瘤的研究进展.丝素蛋白作为抗肿瘤药物的递送载体具有广阔应用前景和重要意义.
Silk fibroin is a type of natural polymer that has good biocompatibility,biodegradability and is also easy to modify.It also possesses low cytotoxicity and is non-immunogenic and therefore it is widely used for the delivery of anti-tumor drugs.Most anti-tumor drugs suffer from low solubility,poor pharmacokinetics and high off-target toxicity.Therefore finding and developing appropriate drug delivery systems is urgently requires to solve these problems and improve the treatment of patients.This paper briefly reviews the structure and characteristics of silk fibroin,the preparation and the different types as well as the research progress of silk fibroin nano-carriers for anti-tumor drugs delivery.This paper also summerizes the research progress of silk fibroin nanocarrier application in photo-dynamic,photothermal and gene therapy for the treatment of malignant tumors.Based on our summery,silk fibroin has prospects for a broad application as a delivery system of anti-tumor drugs.Therefor it seems that silk fibroin will be a promising and important carrier material for novel formulations of anti-tumor drugs.

silk fibroinnanocarrieranti-tumor drug delivery systemphotodynamic therapyphotothermal therapygene therapy

王雪军、李明娟、张洁、高欢、杨根生、丁宝月

展开 >

嘉兴学院医学院,浙江嘉兴 314001

浙江工业大学药学院,杭州 310014

丝素蛋白 纳米载体 抗肿瘤药物递送系统 光动力治疗 光热治疗 基因治疗

国家自然科学基金面上项目浙江省基础公益技术研究计划浙江省基础公益技术研究计划浙江省基础公益技术研究计划青海省重点研发与转化计划嘉兴市科技计划嘉兴市科技计划

81872220LGD21H300001LGD20H300001LGF20H3000122021-SF-C202019AY320092019AY32012

2024

10.11669/cpj.2024.05.001

中国药学杂志
中国药学会

中国药学杂志

CSTPCD北大核心
影响因子：0.957
ISSN：1001-2494
年,卷(期)：2024.59(5)
  • 79